725 related articles for article (PubMed ID: 29460922)
1. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Davies AH; Beltran H; Zoubeidi A
Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
[TBL] [Abstract][Full Text] [Related]
2. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
3. Regulation of tumor cell plasticity by the androgen receptor in prostate cancer.
Bishop JL; Davies A; Ketola K; Zoubeidi A
Endocr Relat Cancer; 2015 Jun; 22(3):R165-82. PubMed ID: 25934687
[TBL] [Abstract][Full Text] [Related]
4. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
5. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
6. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
7. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.
Yin L; Ye Y; Zou L; Lin J; Dai Y; Fu Y; Liu Y; Peng Y; Gao Y; Fu Y; Qi X; Deng T; Zhang S; Li X
J Exp Clin Cancer Res; 2023 Aug; 42(1):204. PubMed ID: 37563661
[TBL] [Abstract][Full Text] [Related]
8. Resistance to Hormonal Therapy in Prostate Cancer.
Berruti A; Dalla Volta A
Handb Exp Pharmacol; 2018; 249():181-194. PubMed ID: 28353036
[TBL] [Abstract][Full Text] [Related]
9. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Akamatsu S; Inoue T; Ogawa O; Gleave ME
Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873
[TBL] [Abstract][Full Text] [Related]
11. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
[TBL] [Abstract][Full Text] [Related]
12. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
13. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
17. Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy.
Sandhu HS; Portman KL; Zhou X; Zhao J; Rialdi A; Sfakianos JP; Guccione E; Kyprianou N; Zhang B; Mulholland DJ
Cell Rep; 2022 Jul; 40(4):111123. PubMed ID: 35905714
[TBL] [Abstract][Full Text] [Related]
18. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
Ge R; Xu X; Xu P; Li L; Li Z; Bian J
Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
[TBL] [Abstract][Full Text] [Related]
19. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
20. Lineage plasticity-mediated therapy resistance in prostate cancer.
Blee AM; Huang H
Asian J Androl; 2019; 21(3):241-248. PubMed ID: 29900883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
